Status:
COMPLETED
Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders
Lead Sponsor:
Stanford University
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Myelodysplastic Syndromes
Myeloproliferative Disorders
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.
Detailed Description
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)
Eligibility Criteria
Inclusion
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- HLA matched donor available
Exclusion
- organ dysfunction
- HIV positive
Key Trial Info
Start Date :
December 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00186576
Start Date
December 1 2001
End Date
July 1 2010
Last Update
October 14 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305